In response to the Surgeon General's call to make naloxone widely available it was announced today at NatCon18, the annual conference of National Council for Behavioral Health, that pharmaceutical companies, Adapt Pharma and Kaleo, are donating doses of naloxone, a potentially lifesaving drug that can help reverse opioid overdoses, to the National
Office Address: Department of the Army; Army Contracting Command; ACC- APG Natick; 10 General Green AvenueBuilding 1 Natick MA 01760-5011. Description: Department of the Army. DynPort Vaccine Company LLC, a General Dynamics Information Technology Company, a biopharmaceutical company in Frederick, Maryland, is issuing this Request for Information to
Office Address: Department of the Army; U.S. Army Medical Command; REGIONAL HEALTH CONTRACT OFF CENTRAL; ATTN: MCAA GP L31 9 V2539 GARDEN AVENUE JBSA FT SAM HOUSTON TX 78234-0000. Contact: Timothy T. Hoerz, Phone 2542856747, Email firstname.lastname@example.org. Description: Department of the Army.
Albany, NY 04/25/2018 Digestible Medical Sensor helps the doctor/caregiver get patient data on mobile application. Digestible Medical senor will be used for medical adherence and study vital signs. Digestible medical Sensor is a new technology in the market with recent FDA approval to market in United States and Europe.
On March 28, 2018, pSivida Corp. acquired specialty biopharmaceutical company Icon Bioscience Inc. pSivida Corp. rebranded and changed its name to EyePoint Pharmaceuticals Inc., with ticker EYPT, effective April 2, 2018. DEXYCU, a dropless, long-acting therapeutic, which was approved by the FDA for the treatment of inflammation in post catara
Bill Burns elected Chairman of Molecular Partners at the 2018 AGM on April 18 Talent base with 113 full-time employees, reflecting further build-out of oncology expertise. ZURICH- SCHLIEREN, SWITZERLAND/ ACCESSWIRE/ April 26, 2018/ Molecular Partners AG, a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin t
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that five abstracts were accepted at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting in Honolulu, Hawaii, April 29 May 3,
Albany, NY 04/25/2018 Drug rescue is also termed as rescue medicines. These are given only when needed or in emergency cases. Drug which is given to counter or block the effect of other medicines are called as rescue medicines.
Albany, NY 04/26/2018 A biosimilar medicine possesses similar pharmacokinetic and mode of action as an original biological medicine that has already been approved for therapeutic use. Biosimilars are made from a living organism such as bacteria and yeast or can also be derived from small molecules such as human insulin, erythropoietin, and mo
STOCKHOLM, April 26st, 2018- On May 8th 2018, at 08:00 am, Moberg Pharma AB will present its interim report for January- March 2018. The teleconference will be hosted by Moberg Pharmas's CEO Peter Wolpert and CFO Anna Ljung. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company with OTC sales
By a News Reporter-Staff News Editor at Gene Therapy Weekly Pfizer Inc. has initiated a Phase 1 b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy. "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfiz
Doris O. Matsui, D- California, issued the following opening remarks at the House Energy and Commerce subcommittee on Health markup on opioid legislation and the Animal Drug and Animal Generic Drug User Fee Amendments:. "Our Committee has a daunting, yet absolutely essential, task before us today: to make policy changes that address the opioid epi
Albany, NY 04/25/2018 The packaging industry is witnessing an impressive growth over the past few years and various new packaging solutions are launched in order to cater increasing need of customers. Packaging of medicines is a complicated process, due to its complex molecular structure of chemicals used in origination of drugs. So, there is
Saniona, a leading biotech company in the field of ion channels, today announced that it has obtained approval to initiate the second part of its Phase 2 a trial for Tesomet in adolescents with Prader-Willi syndrome. By pursuing an orphan indication such as Prader-Willi syndrome, we may develop and commercialize our own product in the U.S. and Euro
The European Medicines Agency issued the following news release:. The European Network of Paediatric Research at the European Medicines Agency will hold its tenth annual workshop on 7-8 June 2018 at the European Medicines Agency. It counts forty six member networks from Europe, Canada, Japan and the United States.
Albany, NY 04/25/2018 Vitamin deficiency, also called as hypovitaminosis, is primarily caused by malnutrition. The rate of undernourishment is high in undeveloped and developing countries such as Africa, Vienna and some parts of South-East Asia. Vitamin deficiency can lead to various diseases such as vitamin D deficiency causes rickets, vitam
Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome. Glepaglutide is in development as a new treatment option for patients with short bowel syndrome The pivotal phase 3 trial is on track for initiation in Q3 2018 Copenhagen, Denmark, April 26, 2018- Zealand Pharma today announced receipt of the End-
22nd Century Group, Inc., a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Company is committed to working collaboratively with the U.S. Food and Drug Administration on the FDA s planned nicotine reduction mandate despite the fact that, last week, regulations.gov published re
-Acasti Pharma Inc. is pleased to announce that, in connection with its overnight marketed public offering previously announced on April 23, 2018, it has entered into an underwriting agreement with Mackie Research Capital Corporation to sell 9,530,000 units of the Company at a price of CDN $1.05 per Unit, with each such Unit comprising one common s
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 9th, 2018. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time on May 9th, 2018 to discuss the financial results and provide a corpora
Acetylon Pharmaceuticals, Boston, Massachusetts, has been assigned a patent developed by two co-inventors for "combinations of histone deacetylase inhibitors and immunomodulatory drugs." The co-inventors are Steven Norman Quayle, Brookline, Massachusetts, and Simon Stewart Jones, Harvard, Massachusetts. Written by Sudarshan Harpal; edited by Sudars
LAUSANNE, Switzerland ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates targeting major cancers, today announced that it has terminated the Phase I clinical trial to evaluate its antibody drug conjugate ADCT-502 in patients with advanced solid tumors
-ADMA Biologics, Inc., today announced that it has successfully completed the manufacturing, release and has made commercial sales of its first batch of Nabi-HB, produced under its leadership. ADMA Biologics is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for t
AHP- Adult diaper sales are expected to plummet as results from a clinical trial on a new, patented bladder control pill have finally been released. Sold under the brand name UriVarx?, the new pill contains key ingredients that keeps the bladder from releasing voluntarily, which reduces accidents and fretiuent bathroom trips. Bassam Damaj of Inno
Slayback Pharma today announced that CEO, Ajay Singh of Slayback Pharma LLC is named as one of the finalists for Ernst and Young's Entrepreneur Of The Year 2018 Award in the New Jersey region. Ajay Singh was selected as a finalist by a panel of independent judges. In the New Jersey, regional sponsor include PNC Bank, DLA Piper, Morgan Lewis, P